THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING DISEASES THAT INVOLVE ANGIOGENESIS

According to the present invention, S100A4 protein also known as Mts-1 interferes with the function of Annexin 2 and Annexing/P 11 tetramer by binding to Annexin 2. The present inventors have demonstrated that binding of S100A4 with Annaxin 2 modulates angiogenesis by interfering with Annexin 2 medi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	OCHIETTE, BENOIT, ALAKHOV, VALERY, PIETRZYNSKI, GRZEGORZ, IOURTCHENKO, LUDMILA, SEMOV, ALEXANDER, ONICHTCHENKO, ANATOLI
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	According to the present invention, S100A4 protein also known as Mts-1 interferes with the function of Annexin 2 and Annexing/P 11 tetramer by binding to Annexin 2. The present inventors have demonstrated that binding of S100A4 with Annaxin 2 modulates angiogenesis by interfering with Annexin 2 mediated tissue plasminogen activator (tPA) dependant conversion of plaminogen into plasmin and further conversion of plasmin into angiostatins. The present invention has further identified that the S100A4 protein binds to the N-terminal region of Annexin 2. Accordingly, the present invention discloses peptides and pharmaceutical compositions thereof and methods of treating cancers and other diseases that involve angiogenesis, by interfering with the interaction between S100A4 and Annexin. L'invention concerne une protéine S100A4, également appelée Mts-1, qui entrave la fonction de l'annexine 2 et du tétramère annexine 2/P11 par une liaison à l'annexine 2. L'invention a permis d'établir le fait que la liaison de S100A4 à l'annexine 2 modulait l'angiogenèse en entravant la conversion de plasminogène en plasmine et la conversion de plasmine en angiostatines, conversions qui dépendent d'un activateur de plasminogène tissulaire (tPA) induit par l'annexine 2. La présente invention a également montré que la protéine S100A4 se liait à la région N-terminal de l'annexine 2. L'invention concerne également des peptides et des compositions pharmaceutiques les contenant, ainsi que des méthodes de traitement des cancers et autres maladies impliquant l'angiogenèse, par entrave de l'interaction entre S100A4 et l'annexine.